ArticleJournal of neurology2026
Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEstrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited. STUDY
designThe FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting.
resultsThere were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases).
conclusionClinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.
Indexed as
Identifiers
42141300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.